Preclinical childhood sarcoma models: Drug efficacy biomarker identification and validation

Brian Geier, Dias Kurmashev, Raushan T. Kurmasheva, Peter J. Houghton

Producción científica: Review articlerevisión exhaustiva

13 Citas (Scopus)


Over the past 35 years, cure rates for pediatric cancers have increased dramatically. However, it is clear that further dose intensification using cytotoxic agents or radiation therapy is not possible without enhancing morbidity and long-term effects. Consequently, novel, less genotoxic, agents are being sought to complement existing treatments. Here, we discuss preclinical human tumor xenograft models of pediatric cancers that may be used practically to identify novel agents for soft tissue and bone sarcomas, and "omics" approaches to identifying biomarkers that may identify sensitive and resistant tumors to these agents.

Idioma originalEnglish (US)
Número de artículo193
PublicaciónFrontiers in Oncology
EstadoPublished - 2015

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Profundice en los temas de investigación de 'Preclinical childhood sarcoma models: Drug efficacy biomarker identification and validation'. En conjunto forman una huella única.

Citar esto